Dazuu, My calculations suggest the infusions business is worth very little. The GPM appears less than 50% and, given sales staff and admin support costs, it's likely marginally profitable. Lucky if it is worth a small fraction of your estimated low end. On a revenue multiple, the ADAPT business (not TAVR) could be worth between $30m to $40 million. However, the company does not appear willing to sell (perhaps, no buyer) but seems intent on playing chicken with receivership prospects. An imminent TAVR licensing deal is really shareholders' only saviour.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.07 |
Change
0.160(3.26%) |
Mkt cap ! $74.26M | |||
| Open | High | Low | Value | Volume |
| $4.85 | $5.07 | $4.79 | $12.37K | 2.553K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1574 | $4.82 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.07 | 1775 | 1 |
View Market Depth
| Last trade - 13.07pm 22/07/2025 (20 minute delay) ? |
| AVR (ASX) Chart |